得力生注射液抗癌症恶病质的临床研究  

Clinical study on anti-cancer cachexia of Delisheng Injection

作　　者：吕晶晶[1] 李庆云[1] 方小玲[1] 

机构地区：[1]河南省焦作市第二人民医院肿瘤内科,454000

出　　处：《中国医疗前沿》2010年第19期45-45,4,共2页China Healthcare Innovation

摘　　要：目的观察得力生注射液对癌性恶病质状态的影响。方法给予癌症恶病质患者3周得力生注射液,每天50ml,观察治疗前后体重、症状及恶病质相关因子的变化。结果治疗后与治疗前相比,患者在食欲、体重、体能评分方面明显改善,细胞因子TNF-α、IL-6、IL-1均有不同程度下降。结论得力生在一定程度上可能通过下调恶病质细胞因子,从而改善患者的生存质量。Objective To study the efficacy of Delisheng Injection in the treatment of cancer cachexia. Method Three weeks dosage of Delisheng Injection were prescribed to the patients with cancer cachexia,50ml per day,symptoms and the level of cancer cachexia correlated cell factors were observed. Results Patients got better after treatment in the appetite,weight,physical status,while the level of the cell factors descended. Conclusion Delisheng Injection can regulated the level of the cell factors and improve the quality of life.

关 键 词：肿瘤 得力生注射液 恶病质相关细胞因子 

分 类 号：R730.52[医药卫生—肿瘤]